公开(公告)号：EP2286235A1

公开(公告)日：2011-02-23

申请号：EP09765711.8

申请日：2009-05-25

申请人： BASF SE ,  Looser, Ralf

发明人： RAVENZWAAY, Bennard van ,  MELLERT, Werner ,  COELHO PALERMO CUNHA, Georgia ,  FABIAN, Eric ,  STRAUSS, Volker ,  KAMP, Hennicke ,  WALK, Tilmann, B. ,  HEROLD, Michael, Manfred ,  WIEMER, Jan, C. ,  PROKOUDINE, Alexandre ,  LEIBOLD, Edgar ,  LOOSER, Ralf

IPC分类号： G01N33/66 ,  G01N33/92 ,  G01N33/84

CPC分类号： G01N33/66 ,  G01N33/84 ,  G01N33/92 ,  G01N2405/00 ,  G01N2500/00 ,  G01N2800/085 ,  G01N2800/50 ,  G01N2800/60

摘要： The present invention pertains to the field of toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing the pro-pathological effect of compounds which are inducing liver enzymes. It also relates to a method of determining whether a compound is capable of exhibiting pro-pathological effects on the liver by enzyme induction in a subject and to a method of identifying a drug for treating the pro-pathological effect of liver enzyme induction. Furthermore, the present invention relates to a data collection comprising characteristic values of at least five analytes, a data storage medium comprising said data collection, and a system and a device for diagnosing the pro-pathological effect of liver enzyme induction. Finally, the present invention pertains to the use of a group of analytes or means for the determination thereof for the manufacture of a diagnostic device or composition for diagnosing the pro-pathological effect of liver enzyme induction in a subject. For each sex, a different metabolome pattern, i.e. a different set of analytes is disclosed. The liver enzyme induction markers are mainly selected from free fatty acids, but also include various phosphatidylcholines, galactose, 3- and 5-Methoxysphingosine, Cholesterol, Threonic acid, 1, 2-Dioleoyl-sn-glycero-3-phosphatidyl-L-serine, Glycerol, Glycerophosphate, Dodecanol, myo-Inositol-2-monophosphate.

摘要翻译： 本发明涉及化学化合物危险分层的毒理学评估领域。 具体地说，本发明涉及一种用于诊断诱导肝酶的化合物的前病理作用的方法。 本发明还涉及一种确定化合物能否通过受试者的酶诱导对肝脏具有前病理作用的方法以及用于鉴定用于治疗肝酶诱导的前病理作用的药物的方法。 此外，本发明涉及包含至少五种分析物的特征值的数据收集，包括所述数据收集的数据存储介质，以及用于诊断肝酶诱导的病理学作用的系统和装置。 最后，本发明涉及一组分析物或方法用于制备诊断装置或组合物在诊断受试者肝酶诱导的病理学作用的用途。 对于每个性别，公开了不同的代谢组型，即不同的分析物组。 肝酶诱导标志物主要选自游离脂肪酸，还包括各种磷脂酰胆碱，半乳糖，3-和5-甲氧基鞘氨醇，胆固醇，苏氨酸，1,2-二油酰-sn-甘油-3-磷脂酰-L-丝氨酸 甘油，甘油磷酸酯，十二烷醇，肌醇-2-单磷酸。